A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

trastuzumab

Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression

DRUG

paclitaxel

60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression

DRUG

Myocet

40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles

Trial Locations (1)

28027

Madrid

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02015676 - A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer | Biotech Hunter | Biotech Hunter